Advanced Biomed Net Income Over Time
| ADVB Stock | 0.31 0 0.97% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Advanced Biomed Performance and Advanced Biomed Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Advanced Biomed. If investors know Advanced will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Advanced Biomed assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Advanced Biomed Common requires distinguishing between market price and book value, where the latter reflects Advanced's accounting equity. The concept of intrinsic value—what Advanced Biomed's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Advanced Biomed's price substantially above or below its fundamental value.
Understanding that Advanced Biomed's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Advanced Biomed represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Advanced Biomed's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Advanced Biomed Common and related stocks such as BioNexus Gene Lab, Trinity Biotech plc, and Ridgetech Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGLC | (835) | (835) | (835) | (835) | (835) | (835) | (835) | (123.8 K) | 26.5 K | (246.5 K) | 1.1 M | 751.6 K | (356 K) | (2.6 M) | (1.6 M) | (1.4 M) | (1.4 M) |
| TRIB | (3.4 M) | 15.6 M | 17.3 M | 10.3 M | 17.2 M | 21.8 M | (100.6 M) | (40.3 M) | 2.4 M | (4.1 M) | (6.4 M) | 875 K | (41 M) | (24 M) | (31.8 M) | (28.6 M) | (27.2 M) |
| RDGT | (3.7 K) | 8.1 M | (14.3 M) | (25.4 M) | 856.6 K | 447.2 K | (5.6 M) | (17.1 M) | (926.3 K) | (5.8 M) | (8.1 M) | (3.2 M) | (21.1 M) | (4.2 M) | 10.2 M | 9.2 M | 9.6 M |
| APM | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.5 M) | (14.8 M) | (18.7 M) | 7.1 M | (25 M) | (9.8 M) | (2.8 M) | (4.3 M) | (3.8 M) | (4 M) |
| XAIR | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (4.8 M) | (3.7 M) | (29.7 K) | (18 M) | (6.6 M) | (19.9 M) | (22.9 M) | (43.2 M) | (55.8 M) | (60.2 M) | (46.6 M) | (42 M) | (39.9 M) |
| MRKR | (1.1 M) | (2 M) | (5.9 M) | (5.5 M) | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (8.2 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| MBIO | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (12.7 M) | (31.3 M) | (30.7 M) | (48.2 M) | (60 M) | (66.4 M) | (77.5 M) | (51.6 M) | (15.8 M) | (14.2 M) | (14.9 M) |
| TNON | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (509.6 K) | (585.2 K) | (7 M) | (18.9 M) | (15.6 M) | (13.7 M) | (12.3 M) | (12.9 M) |
| GELS | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (375.6 K) | (648.9 K) | (3.4 M) | (3.5 M) | (3.5 M) | (6.6 M) | (6 M) | (5.7 M) |
Advanced Biomed Common and related stocks such as BioNexus Gene Lab, Trinity Biotech plc, and Ridgetech Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Advanced Biomed Common financial statement analysis. It represents the amount of money remaining after all of Advanced Biomed Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Advanced Biomed Common | ADVB |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 122 East 42nd |
| Exchange | NASDAQ Exchange |
null 0.307
Check out Advanced Biomed Performance and Advanced Biomed Correlation. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Advanced Biomed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.